Solara Active Pharma Sciences Limited (SOLARA) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Solara Active Pharma Sciences Limited stock ₹145, price ₹636, that is 77.2% below the price, quality 33 out of 100. Rating: strongly overvalued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Solara Active Pharma Sciences Limited
SOLARA · NSEFar too expensive (fair value 77% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.
How to read this chart
60‑month range ₹297.85 – ₹1,775 · fair‑value band ₹83.78 – ₹210.41 · the ₹635.65 price screens above the ₹144.87 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.
Every Wednesday you see whether Solara Active Pharma Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally.
Show moreShow less
The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotic, anticonvulsant, antidepressant, antifibrinolytics, antigout agent, antihelmintic, antihistamine, antihyperlipoproteinemic, antimycotic, antifungal, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antiulcer, antiulcerative, anxiolytic, aprepitant, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, immune-suppressant, loop diuretic, NSAIDs, anti-hyperkalaemia, nucleoside inhibitor, OAB treatment, phenylalanine reducer, phosphate binder, reversal of neuro-muscular blocking agent, skeletal muscle relaxant, and topical anti-infectives.
It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical development, impurity synthesis, and regulatory support. In addition, the company exports its products.
The company was formerly known as SSL Pharma Sciences Limited and changed its name to Solara Active Pharma Sciences Limited in March 2017. Solara Active Pharma Sciences Limited was incorporated in 2017 and is based in Chennai, India.
Stock analysis
Solara Active Pharma Sciences Limited (SOLARA) currently trades at ₹635.65, while our model-based Fair Value estimate is ₹144.87, 77% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹175.53 per share, and 0 of the 13 models we run sit above the ₹635.65 price.
Bear case: the Earnings-Based group reads lowest at ₹54.24, and 13 of the 13 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ₹83.78 (bear) to ₹210.41 (bull), the price of ₹635.65 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Solara Active Pharma Sciences Limited reported revenue of ₹13.7B in FY2026 versus ₹12.7B in FY2022, a compound +1.9%/yr. Reported net income was −₹74.1M in FY2026.
Key figures
Market cap ₹30.6B (≈ $324M) Small · P/E ratio 82.2 · P/S ratio 1.99 · EPS (TTM) ₹7.71 · Net margin 2.4% · Return on equity 2.7% · Return on assets (EBIT) 1.3% (5-year average) · Operating margin 12.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 16% below its 52-week high and 49% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −77%, SOLARA screens richer than that median.
Fair Value models
All 13 models by family
The fair value above starts from this blend and is adjusted for dilution from new shares.
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
SOLARA screens overvalued: fair value 77% below the price. Compare with Merck KGaA →
Compare Solara Active Pharma Sciences Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- P/B ratio by industry
- Net margin by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $83.82 | $113.53 | +35% | vs SOLARA |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.02 | ¥53.04 | +10% | vs SOLARA |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,868 | ₹1,983 | +6% | vs SOLARA |
| Haleon plc HLN | $9.17 | $8.47 | −8% | vs SOLARA |
| Merck KGaA MRK | €149.70 | €108.83 | −27% | vs SOLARA |
| Galderma Group GALD | CHF 191.00 | CHF 112.30 | −41% | vs SOLARA |
| Takeda Pharmaceutical Company TAK | $21.43 | $11.20 | −48% | vs SOLARA |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs SOLARA |
| Teva Pharmaceutical Industries Limited TEVA | $44.50 | $20.74 | −53% | vs SOLARA |
| Divi's Laboratories Limited DIVISLAB | ₹11,080 | ₹1,567 | −86% | vs SOLARA |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Solara Active Pharma Sciences Limited (SOLARA) overvalued or undervalued?
What is the fair value of SOLARA?
What is the quality score of SOLARA?
What is the price target for Solara Active Pharma Sciences Limited (SOLARA)?
What is the Solara Active Pharma Sciences Limited stock forecast for 2026?
What is the revenue of Solara Active Pharma Sciences Limited (SOLARA)?
What growth is priced into Solara Active Pharma Sciences Limited (SOLARA)?
What discount rate (WACC) does the fair value of SOLARA use?
What is a reverse DCF?
How much growth has Solara Active Pharma Sciences Limited (SOLARA) delivered so far?
How fast is the sector of Solara Active Pharma Sciences Limited (SOLARA) growing?
What is the free cash flow yield of Solara Active Pharma Sciences Limited (SOLARA)?
What is the intrinsic value of Solara Active Pharma Sciences Limited (SOLARA)?
Is Solara Active Pharma Sciences Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of SOLARA?
How much is Solara Active Pharma Sciences Limited worth?
What do the bullish and bearish scenarios say about SOLARA?
What is the P/E ratio of SOLARA?
How solid is the balance sheet of Solara Active Pharma Sciences Limited (SOLARA)?
How far is SOLARA from its 52-week high?
Which stocks are comparable to Solara Active Pharma Sciences Limited?
Is Solara Active Pharma Sciences Limited stock attractive at the current price?
How is the fair value of SOLARA calculated?
Is it still worth investing in stocks now?
What is the share price of Solara Active Pharma Sciences Limited (SOLARA)?
What should I pay attention to with Solara Active Pharma Sciences Limited right now?
Key figures of Solara Active Pharma Sciences Limited
How large is the market capitalisation of Solara Active Pharma Sciences Limited (SOLARA)?
What is the P/S ratio of Solara Active Pharma Sciences Limited (SOLARA)?
What are the earnings per share of Solara Active Pharma Sciences Limited (SOLARA)?
What is the net margin of Solara Active Pharma Sciences Limited (SOLARA)?
What is the return on equity of Solara Active Pharma Sciences Limited (SOLARA)?
What is the EBIT return on assets of Solara Active Pharma Sciences Limited (SOLARA)?
What is the operating margin of Solara Active Pharma Sciences Limited (SOLARA)?
How fast is revenue growing at Solara Active Pharma Sciences Limited (SOLARA)?
How fast are earnings growing at Solara Active Pharma Sciences Limited (SOLARA)?
How much net debt does Solara Active Pharma Sciences Limited (SOLARA) carry?
Watch Solara Active Pharma Sciences Limited in the live analysis
One click puts Solara Active Pharma Sciences Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.